Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q3 FY20 results · Oct–Dec 2019
Marksans Pharma reported revenue from operations of ₹287.65 crore (up 15.8% from Q3 FY19) and net profit of ₹29.56 crore (up 17.6% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 287.65 | 248.37 | +15.8% | 256.40 | +12.2% |
| Other income | 0.03 | 0.16 | −83.4% | 7.88 | −99.7% |
| Total income | 287.68 | 248.52 | +15.8% | 264.28 | +8.9% |
| Profit before tax | 38.34 | 29.55 | +29.7% | 33.66 | +13.9% |
| Net profit for the period | 29.56 | 25.13 | +17.6% | 25.97 | +13.8% |
| EPS, basic (₹) | 0.71 | 0.60 | +18.3% | 0.63 | +12.7% |
| Net margin (%) | 10.3 | 10.1 | 10.1 |
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 116.88 | 125.19 | −6.6% | 100.72 | +16.0% |
| Other income | 0.01 | 0.12 | −94.1% | 7.87 | −99.9% |
| Total income | 116.89 | 125.31 | −6.7% | 108.58 | +7.6% |
| Profit before tax | 16.12 | 13.98 | +15.3% | 15.53 | +3.8% |
| Net profit for the period | 12.97 | 11.78 | +10.1% | 11.86 | +9.4% |
| EPS, basic (₹) | 0.32 | 0.29 | +10.3% | 0.29 | +10.3% |
| Net margin (%) | 11.1 | 9.4 | 11.8 |
Consolidated
- Filed with BSE
- 12 Feb 2020, 14:21 IST
- Board meeting
- 11 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Feb 2020, 14:21 IST
- Board meeting
- 11 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE